NADAC acquisition cost data for PROCHLORPERAZINE 10 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378511001 | $0.4279 | 2022-12-21 | Rx |
| 50268068511 | $0.4279 | 2022-12-21 | Rx |
| 50268068515 | $0.4279 | 2022-12-21 | Rx |
| 59746011506 | $0.4279 | 2022-12-21 | Rx |
| 70710166801 | $0.4279 | 2022-12-21 | Rx |
| 70954068910 | $0.4279 | 2022-12-21 | Rx |
| 00378511001 | $0.4279 | 2022-12-21 | Rx |
| 50268068511 | $0.4279 | 2022-12-21 | Rx |
| 50268068515 | $0.4279 | 2022-12-21 | Rx |
| 59746011506 | $0.4279 | 2022-12-21 | Rx |
Generic: Prochlorperazine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.1M | 9,029 | 6,563 | $7.43 |
| 2020 | $1.2M | 8,757 | 6,199 | $7.76 |
| 2021 | $1.0M | 8,249 | 5,829 | $7.31 |
| 2022 | $877.2K | 7,425 | 5,366 | $7.19 |
| 2023 | $380.4K | 3,267 | 2,594 | $7.77 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $41.2K | 309 | 248 |
| California | $37.0K | 273 | 213 |
| New York | $31.9K | 264 | 215 |
| Michigan | $25.0K | 285 | 254 |
| Pennsylvania | $18.2K | 183 | 137 |
| New Jersey | $16.1K | 134 | 122 |
| Massachusetts | $14.8K | 105 | 75 |
| Illinois | $14.0K | 108 | 90 |
| Wisconsin | $12.4K | 111 | 66 |
| Oregon | $12.2K | 98 | 68 |
| Ohio | $12.0K | 90 | 68 |
| Washington | $10.6K | 99 | 86 |
| Arizona | $10.4K | 71 | 46 |
| Maryland | $10.0K | 70 | 52 |
| Texas | $9.7K | 77 | 59 |
| Georgia | $7.9K | 75 | 63 |
| North Carolina | $7.1K | 57 | 47 |
| Connecticut | $6.8K | 63 | 48 |
| Virginia | $6.8K | 47 | 34 |
| Minnesota | $6.7K | 70 | 54 |
| Missouri | $6.6K | 72 | 65 |
| Colorado | $5.6K | 55 | 49 |
| South Carolina | $4.7K | 26 | 17 |
| New Mexico | $4.5K | 39 | 33 |
| Tennessee | $4.5K | 39 | 35 |
| Alabama | $4.3K | 72 | 68 |
| Nevada | $3.3K | 20 | 15 |
| Iowa | $3.0K | 29 | 25 |
| Arkansas | $2.9K | 24 | 17 |
| Kentucky | $2.8K | 16 | N/A |
| Maine | $2.6K | 38 | 27 |
| Indiana | $2.3K | 25 | 21 |
| Utah | $2.2K | 15 | 12 |
| Alaska | $2.2K | 12 | N/A |
| Kansas | $2.1K | 20 | 17 |
| Vermont | $2.0K | 20 | 14 |
| Oklahoma | $2.0K | 23 | 18 |
| Delaware | $1.6K | 17 | 15 |
| Montana | $1.5K | 11 | N/A |
| Rhode Island | $1.4K | 17 | 16 |
| Louisiana | $1.3K | 16 | 15 |
| South Dakota | $1.3K | 14 | 13 |
| New Hampshire | $1.2K | 14 | 14 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.